PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-23.20%
Negative net income growth while CRVO stands at 31.80%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
3.49%
Some D&A expansion while CRVO is negative at -0.20%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-100.00%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
19.58%
Less SBC growth vs. CRVO's 47.04%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
19.36%
Slight usage while CRVO is negative at -336.63%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
55.56%
A yoy AP increase while CRVO is negative at -272.40%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-124.52%
Both reduce yoy usage, with CRVO at -564.33%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
56.31%
Growth of 56.31% while CRVO is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might reflect intangible expansions or partial write-offs.
-16.84%
Both yoy CFO lines are negative, with CRVO at -43.74%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
100.00%
CapEx growth of 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We expand invests by 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
-594.74%
We cut debt repayment yoy while CRVO is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.